Spray-Congealing and Wet-Sieving as Alternative Processes for Engineering of Inhalation Carrier Particles: Comparison of Surface Properties, Blending and In Vitro Performance.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 19 03 2021
accepted: 12 05 2021
pubmed: 12 6 2021
medline: 15 12 2021
entrez: 11 6 2021
Statut: ppublish

Résumé

Traditionally, α-lactose monohydrate is the carrier of choice in dry powder inhaler (DPI) formulations. Nonetheless, other sugars, such as D-mannitol, have emerged as potential alternatives. Herein, we explored different particle engineering processes to produce D-mannitol carriers for inhaled delivery. Wet-sieving and spray-congealing were employed as innovative techniques to evaluate the impact of engineering on the particle properties of D-mannitol. To that end, the resulting powders were characterized concerning their solid-state, micromeritics and flowability. Afterwards, the engineered carrier particles were blended with inhalable size beclomethasone dipropionate to form low dose (1 wt%) DPI formulations. The in vitro aerosolization performance was evaluated using the NEXThaler®, a reservoir multi-dose device. Wet-sieving generated D-mannitol particles with a narrow particle size distribution and spray-congealing free-flowing spherical particles. The more uniform pumice particles with deep voids and clefts of wet-sieved D-mannitol (Pearl300_WS) were beneficial to drug aerosolization, only when used in combination with a ternary agent (10 wt% of 'Preblend'). When compared to the starting material, the spray-congealed D-mannitol has shown to be promising in terms of the relative increase of the fine particle fraction of the drug (around 100%), when used without the addition of ternary agents. The wet-sieving process and the related aerosolization performance are strongly dependent on the topography and structure of the starting material. Spray-congealing, has shown to be a potential process for generating smooth spherical particles of D-mannitol that enhance the in vitro aerosolization performance in binary blends of the carrier with a low drug dose.

Identifiants

pubmed: 34114162
doi: 10.1007/s11095-021-03061-5
pii: 10.1007/s11095-021-03061-5
pmc: PMC8217042
doi:

Substances chimiques

Anti-Asthmatic Agents 0
Drug Carriers 0
Mannitol 3OWL53L36A
Beclomethasone KGZ1SLC28Z

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1107-1123

Références

Int J Pharm. 2008 Feb 4;348(1-2):10-7
pubmed: 17689898
Int J Pharm. 2019 Feb 25;557:342-353
pubmed: 30599227
Pharm Res. 2006 Aug;23(8):1665-74
pubmed: 16845584
Int J Pharm. 2015 Jan 15;478(1):53-59
pubmed: 25448567
AAPS PharmSciTech. 2013 Sep;14(3):1158-68
pubmed: 23897035
Eur J Pharm Biopharm. 2012 Sep;82(1):194-204
pubmed: 22595133
Eur J Pharm Biopharm. 2015 Oct;96:291-303
pubmed: 26275831
Drug Dev Ind Pharm. 2009 Aug;35(8):904-16
pubmed: 19466888
Int J Pharm. 2012 May 10;427(2):224-33
pubmed: 22349053
J Pharm Sci. 2000 Apr;89(4):457-68
pubmed: 10737907
Int J Pharm. 2011 Jul 15;413(1-2):93-102
pubmed: 21540087
Int J Pharm. 2020 Mar 15;577:118901
pubmed: 31846726
J Pharm Sci. 2005 May;94(5):1004-12
pubmed: 15793798
Int J Pharm. 2019 Apr 20;561:148-160
pubmed: 30825556
Curr Drug Deliv. 2019;16(3):180-194
pubmed: 30360739
Curr Pharm Des. 2015;21(40):5900-14
pubmed: 26446471
AAPS PharmSciTech. 2014 Dec;15(6):1417-28
pubmed: 24962007
Int J Pharm. 2018 Jan 15;535(1-2):59-67
pubmed: 29100914
Int J Pharm. 2017 May 30;524(1-2):351-363
pubmed: 28347847
Int J Pharm. 2008 Sep 1;361(1-2):131-40
pubmed: 18617338
Int J Pharm. 2006 Feb 17;309(1-2):51-9
pubmed: 16377105
Int J Pharm. 2020 Aug 30;586:119592
pubmed: 32622814
Drug Discov Today. 2014 May;19(5):618-26
pubmed: 24269834
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):167-78
pubmed: 26355743
PLoS One. 2014 Jan 28;9(1):e87825
pubmed: 24489969
Int J Pharm. 2007 Apr 4;334(1-2):103-14
pubmed: 17110062
Int J Pharm. 2020 Dec 15;591:120014
pubmed: 33122114

Auteurs

Joana T Pinto (JT)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010, Graz, Austria.

Sarah Zellnitz (S)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010, Graz, Austria.

Tomaso Guidi (T)

Chiesi Farmaceutici S.p.A., R&D Department, Largo F. Belloli 11/A, 43122, Parma, Italy.

Francesca Schiaretti (F)

Chiesi Farmaceutici S.p.A., R&D Department, Largo F. Belloli 11/A, 43122, Parma, Italy.

Hartmuth Schroettner (H)

Austrian Centre for Electron Microscopy and Nanoanalysis, TU Graz, Steyrergasse 17/III, 8010, Graz, Austria.

Amrit Paudel (A)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010, Graz, Austria. amrit.paudel@rcpe.at.
Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, 8010, Graz, Austria. amrit.paudel@rcpe.at.

Articles similaires

Tumor Microenvironment Nanoparticles Immunotherapy Cellular Senescence Animals
Cobalt Azo Compounds Ferric Compounds Polyesters Photolysis
Neoplastic Stem Cells Animals Humans Aldehyde Dehydrogenase Tretinoin
NLR Family, Pyrin Domain-Containing 3 Protein Autophagy Inflammasomes Interleukin-1beta Animals

Classifications MeSH